Scarica l'app Stockscreener
5.13
1.38%
0.07
Pre-mercato:
5.18
0.05
+0.97%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Recursion Pharmaceuticals stockholders elect three Class I directors - Investing.com Australia
Recursion Pharmaceuticals stockholders elect three Class I directors By Investing.com - Investing.com India
Recursion Pharmaceuticals Holds Annual Stockholder Meeting - TipRanks
Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga
Recursion Pharmaceuticals (RXRX): Morgan Stanley Adjusts Price Target | RXRX Stock News - GuruFocus
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Recursion Pharma to reduce workforce by 20% - MSN
Why Recursion Pharmaceuticals Stock Is Plummeting Today - AOL.com
Recursion Pharmaceuticals price target lowered to $5 by Morgan Stanley - Investing.com Canada
Recursion Pharmaceuticals price target lowered to $5 from $8 at Morgan Stanley - TipRanks
Morgan Stanley Cuts Recursion Pharmaceuticals Price Target to $5 From $8, Maintains Equalweight Rating - MarketScreener
Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy? - MSN
Why Recursion Pharmaceuticals RXRX Could Be the NVDA of Biotech for NASDAQ:RXRX by TopgOptions - TradingView
Recursion to lay off 20% of workforce, narrows focus amid biotech downturn - MSN
Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss By Investing.com - Investing.com South Africa
Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss - Investing.com
Cautious Outlook on Recursion Pharmaceuticals Amid Strategic Restructuring and Cash Management Challenges - TipRanks
Insmed surges on lung drug data; Recursion cuts staff - Yahoo Finance
Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today - MSN
Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI - MSN
Recursion to lay off 20% of workforce amid biotech funding woes - MSN
Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday - MSN
After pipeline cull, AI drug developer Recursion cuts staff by 20% - FirstWord Pharma
Recursion Eliminating 20% of Workforce, Citing Pipeline Pruning and Capital Markets - Genetic Engineering and Biotechnology News
Recursion Pharmaceuticals Stock Surges After Company Lays Off 20% Workforce: Retail Predicts ‘Blue Skies’ Ahead - MSN
Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening? - Benzinga
Recursion Downsizes by 20% To Boost Cash Position - BioSpace
Recursion lays off 20% of staff in wake of pipeline cutbacks - Fierce Biotech
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday - marketscreener.com
Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky (RXRX) - Seeking Alpha
Recursion Cuts 20% of Workforce, Extends Cash Runway to Late 2027 - MarketScreener
Recursion Pharma to reduce workforce by 20% (RXRX:NASDAQ) - Seeking Alpha
Recursion Pharmaceuticals Stock (RXRX): AI Breakthrough for Drug Development - Value The Markets
Recursion Pharmaceuticals (RXRX) Implements Workforce and Operat - GuruFocus
Recursion Pharmaceuticals Announces Workforce Reduction Strategy - TipRanks
Recursion Pharmaceuticals announces 20% workforce reduction - TipRanks
Recursion Pharmaceuticals Announces Personnel And Infrastructure ReductionSEC Filing - marketscreener.com
15 Stocks That Stole The Show Last Week - Insider Monkey
Recursion rises on launch of Boltz-2 in partnership with MIT - MSN
Why Recursion Pharmaceuticals (RXRX) Soared On Friday - Insider Monkey
10 Stocks Are Dominating Like Wall Street Titans - Insider Monkey
Recursion Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:RXRX - Benzinga
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas - mx.advfn.com
Recursion Pharmaceuticals Stock Surges On Breakthrough AI Model Launch With MIT - Benzinga
Recursion Pharmaceuticals shares surge on AI model release By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals shares surge on AI model release - Investing.com
Recursion Pharmaceuticals call volume above normal and directionally bullish - TipRanks
Recursion Pharmaceuticals (RXRX) Sees Surge in Bullish Options Activity | RXRX Stock News - GuruFocus
Recursion (RXRX) Shares Jump on New Biomolecular Model Launch - GuruFocus
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):